# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frédéric Chopin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI020-SYN-TD
- Date: 1838-03-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Matthias Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Results visit: tuberculosis confirmed; infectious diseases consultation and start of treatment. **S**

## History of present illness

Mr. Chopin returns three days after his first visit, masked and seen in an airborne infection isolation room, for his results; Dr. Kowalczyk-Grant of infectious diseases sees him the same morning. He has stayed at home with no students or visitors, and his lessons have moved online. His cough and night sweats are unchanged, and he has coughed up streaks of blood once since the first visit. His three sputum smears show acid-fast bacilli (2+, 2+, and 1+), and the nucleic acid amplification test on the first sample detected Mycobacterium tuberculosis complex with no rifampin resistance; molecular tests for isoniazid and fluoroquinolone resistance and the cultures are pending. The interferon-gamma release assay is positive, HIV is negative, hepatitis B surface antigen and core antibody are negative with surface antibody positive from vaccination, and hepatitis C antibody is negative. He was relieved to have a name for the illness and asked how long treatment lasts and when he can teach again. After the four-month and six-month regimens were explained, he chose the four-month regimen and took his first observed dose with a meal in the clinic. **S**

| Element | Detail |
|---|---|
| Results | Smears 2+, 2+, 1+; amplification test positive without rifampin resistance; IGRA positive; HIV negative; hepatitis B immune; hepatitis C negative |
| Symptoms | Cough, one more streak of blood, night sweats |
| Decision | Four-month rifapentine-moxifloxacin regimen, first dose today |
| Isolation | At home; lessons online |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Cough with morning sputum; one more streak of blood since the first visit; no breathlessness at rest |
| Constitutional | Positive | Night sweats and evening fevers; poor appetite |
| Musculoskeletal | Negative | No tendon or joint pain |
| Neurological | Negative | No numbness or tingling; fine finger movements normal |
| Psychiatric | Positive | Anxious and low, but relieved to know the diagnosis; no thoughts of suicide or self-harm |

5 systems reviewed. **S**

## Current medications

- Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food **S**
- Moxifloxacin 400 mg tablet, one tablet daily **S**
- Isoniazid 300 mg tablet, one tablet daily **S**
- Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 102/64 mmHg; pulse 98 bpm; respirations 18/min; temperature 37.6 °C; oxygen saturation 95% on room air; weight 48.4 kg; BMI 16.7 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Thin and tired; weight 48.4 kg; temperature 37.6 °C, pulse 98; seen in an airborne infection isolation room with a respirator |
| Respiratory | Coarse crackles and bronchial breathing over the right upper zone; fine crackles at the left apex |
| Abdomen | Soft; liver not enlarged |
| Musculoskeletal | Achilles and wrist tendons non-tender, as a baseline before moxifloxacin |
| Neurological | Normal light touch and vibration in the fingers and feet, as a baseline before isoniazid |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pulmonary tuberculosis, cavitary, smear-positive** (A15.0). Confirmed today, replacing the presenting problem of cough, hemoptysis, and weight loss. No rifampin resistance. He meets the criteria for the four-month regimen: over 12 years old, weight 48.4 kg (at least 40 kg), pulmonary disease only, HIV negative, no prolonged QT history and no QT-prolonging or interacting medicines, normal potassium (4.0), magnesium (2.0), liver tests, and creatinine, no earlier tuberculosis treatment, and specimens sent for susceptibility testing before the first dose. Dr. Kowalczyk-Grant agrees. **S**
   - Rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg, and pyrazinamide 1000 mg daily with food for eight weeks, then rifapentine, moxifloxacin, and isoniazid for nine weeks, with pyridoxine 50 mg, by video-observed therapy seven days a week.
   - Three sputum smears in the third week for the release decision; then monthly sputum until two cultures are negative.
   - Liver tests in two to three weeks because of his low weight and albumin; stop the doses and call the same day for yellow eyes, dark urine, vomiting, or abdominal pain.
   - Stop moxifloxacin and call for tendon pain; report numbness or tingling in his fingers.
   - No mineral supplements, antacids, or zinc products within four hours before or eight hours after the dose.
2. **Moderate protein-calorie malnutrition** (E44.0). BMI 16.7 today. Appetite should return as the infection comes under control. **S**
   - First dietitian visit by video this week; supplement drinks in the afternoon and evening, well away from the morning dose.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | Cough, one more streak of blood, night sweats; no improvement yet before treatment |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 48.4 kg: pyrazinamide 1000 mg for the 40 to under 55 kg band |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | Baseline tendon and nerve examination normal; warning symptoms explained |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Up to date | Baseline ALT 18, AST 24, bilirubin 0.5, all normal; repeat ordered for the next visit |
| Laboratory | Potassium, calcium, magnesium, platelets, creatinine | Baseline, then as indicated | Up to date | Baseline potassium 4.0, calcium 9.0, magnesium 2.0, platelets 442 (raised with inflammation), creatinine 0.78 |
| Medication safety | Electrocardiogram (QT interval) | Not routine; only if clinically indicated | Not indicated | No QT history, no QT-prolonging medicines, normal potassium and magnesium |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Three baseline smears 2+, 2+, 1+; cultures pending |
| Laboratory | Nucleic acid amplification test with rifampin resistance | At baseline | Completed today | Mycobacterium tuberculosis complex detected; rifampin resistance not detected |
| Laboratory | Rapid molecular testing for isoniazid and fluoroquinolone resistance | At baseline | Ordered | Sent on the first sample; pending |
| Laboratory | Phenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin) | At baseline | Ordered | On the culture isolate when it grows |
| Laboratory | Interferon-gamma release assay | At baseline | Completed today | Positive; supports, but could not by itself prove or exclude, active tuberculosis |
| Laboratory | HIV test | At baseline | Completed today | HIV-1/2 antigen and antibody negative |
| Laboratory | Hepatitis B and C serology | At baseline | Completed today | Hepatitis B surface antigen and core antibody negative, surface antibody positive (vaccinated); hepatitis C antibody negative |
| Imaging | Chest X-ray | Baseline; at two months only if baseline cultures were negative; end of treatment optional | Up to date | Right upper lobe cavity on X-ray and CT at the first visit |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | Video-observed therapy set up with the health department; first dose observed in clinic today |
| Medication safety | Drug interactions: rifapentine, and mineral products with moxifloxacin | With every new medicine or supplement | Completed today | No other medicines; mineral products to be kept apart from moxifloxacin; orange urine and tears expected |
| Self-management | Home airborne isolation and the release criteria | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Continues at home; lessons online |
| Referral | Report to the health department | Same day as suspicion and on confirmation | Completed today | Suspected case reported at the first visit; confirmation sent today |
| Referral | Contact investigation (students, friends, close contacts) | Led by the health department from diagnosis | Referred | Health department listing his students and other close contacts; their results are not part of his record |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Up to date | 7 at the first visit, item 9 scored 0 |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Ordered | First dietitian visit by video this week |
| Laboratory | Sweat chloride and serum alpha-1 antitrypsin | Once, to address the alternatives | Ordered | Advised by infectious diseases; at the next visit, once he is out of isolation |
| Referral | Infectious diseases review | At diagnosis, at two months, and at the end of treatment | Completed today | Seen today by Dr. Kowalczyk-Grant |

## Goal progress

- Complete all 119 doses within five months by video-observed therapy. In progress; target 1838-07-21. **S**
- Sputum culture negative at two months. In progress; target 1838-07-21. **S**
- Return to teaching once the health department confirms he is no longer infectious. In progress; target 1838-04-07. **S**
- Weight back to at least 55 kg by the end of treatment. In progress; target 1838-07-21. **S**
- PHQ-9 below 5 by the end of treatment. In progress; target 1838-07-21. **S**

## Medication changes

- Started: Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food **S**
- Started: Moxifloxacin 400 mg tablet, one tablet daily **S**
- Started: Isoniazid 300 mg tablet, one tablet daily **S**
- Started: Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily **S**
- Started: Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017), Cystic Fibrosis Foundation (Journal of Pediatrics)
- American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003), American Thoracic Society and European Respiratory Society (American Journal of Respiratory and Critical Care Medicine)
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Release smears in the third week, then review at about two and a half weeks with liver tests, the sweat chloride test, and the alpha-1 antitrypsin level. Call the same day for hepatitis symptoms or tendon pain. **S**
- Next scheduled visit 1838-04-07: two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for cystic fibrosis and alpha-1 antitrypsin deficiency. **S**
